

Structure of human CENP-A-H4-HJURP Complex

Keywords: centromere, CENP-A, histone chaperone

MS.16.1

Acta Cryst. (2011) A67, C51

Engineering immunity against HIV-1 using designed antibody constructs

Pamela J. Bjorkman, Michael A. Anaya, Shiyu Bai, Ron Diskin, Timothy J. Feliciano, Erin P. Flanagin, Rachel P. Galimidi, Han Gao, Priyanthi N. P. Gnanapragasam, Jennifer R. Keeffe, Terri Lee, Paola M. Marcovecchio, Maria D. Politzer, Anthony P. West, Jr., Yunji Wu, Division of Biology, California Institute of Technology, Pasadena, California (USA). E-mail: bjorkman@caltech.edu

Despite decades of effort, no current vaccine elicits neutralizing antibodies at concentrations blocking HIV-1 infection. In addition to structural features of HIV's envelope spike that facilitate antibody evasion, we proposed that the low density and limited lateral mobility of HIV spikes impedes bivalent binding by antibodies via inter-spike cross-linking [1]. In addition, molecular modeling suggested that bivalent binding within a single trimeric spike (intra-spike crosslinking) is also unlikely for antibodies directed against most protein epitopes. The resulting predominantly monovalent binding minimizes avidity and thereby high affinity binding and potent neutralization, thus expanding the range of HIV mutations permitting antibody evasion. In this talk, I will review our efforts to create high avidity anti-HIV protein reagents for use in gene therapy and/or passive immunization. One class of reagents is based upon a naturally-occurring dimeric form of 2G12, a neutralizing antibody that recognizes carbohydrates on the gp120 portion of the HIV spike. 2G12 monomers use both Fabs in an unusual domain-swapped (Fab)2 unit to recognize a constellation of carbohydrates on gp120. We have shown that dimerization of 2G12 leads to enhanced potency against HIV-1 strains that are sensitive to 2G12 monomers and neutralization of strains that are resistant to 2G12 monomers [2]. Thus carbohydrate-binding reagents are a logical starting point for engineering novel bivalent and multivalent antibody architectures capable of intra-spike cross-linking. Another class of engineered reagents we're working on involves fusion of the first two domains of the host receptor CD4 to the variable regions of an antibody recognizing the CD4-induced (CD4i) co-receptor binding site on gp120. We designed, expressed, purified, and tested the neutralization potencies of CD4-CD4i antibody reagents with different architectures, antibody combining sites, and linkers [3]. Implications of a crystal structure of a clade C gp120/CD4/CD4i Fab complex that demonstrates auto-reactive binding between the CD4i antibody and CD4 [4] will also be discussed.

 J.S. Klein, P.J. Bjorkman *PLoS Pathog* 2010, 6(5), e1000908. [2] A.P. West Jr., R.P. Galimidi, C.P. Foglesong, P.N.P. Gnanapragasam, K.E. Huey-Tubman, J.S. Klein, M.D. Suzuki, N.E. Tiangco, J. Vielmetter, P.J. Bjorkman *J. Virol.* 2009, 83, 98-104. [3] A.P. West Jr., R.P. Galimidi, C.P. Foglesong, P.N.P. Gnanapragasam, J.S. Klein, P.J. Bjorkman. *J. Virol.* 2010, 84, 261-269. [4] R. Diskin, P.M. Marcovecchio, P.J. Bjorkman. *Nature Struct. Mol. Biol.* 2010, 17, 608-613.

Keywords: antibodies, HIV-1, gp120

MS.16.2

Acta Cryst. (2011) A67, C51

The multiple personalities of transthyretin

<u>Elisabeth Sauer-Eriksson</u>,^a Anders Olofsson,^b Fredrik Almqvist,^a and Anders Öhman,^a ^aDepartment of Chemistry and ^bDepartment of Medical Biochemistry and Biophysics, Umeå University (Sweden). E-mail: elisabeth.sauer-eriksson@chem.umu.se.

The human plasma protein transthyretin (TTR) is a soluble protein that functions as transport protein for thyroxin. At certain conditions however the normally tetrameric protein dissociates and forms structurally less defined monomeric or dimeric species that are prone to aggregate and form fibrils/amyloids leading to disease — familial amyloidotic polyneuropathy (FAP, type I). One of our aims is to characterize in detail the structural changes in the TTR protein that lead to amyloid formation and disease [1], [2].

To prevent transthyretin fibril formation, one rather successful approach is to stabilize the native state structure, thereby reducing the protein's ability to form the misfolded intermediate structures needed to form fibrils [3]. Even though a number of stabilizing compounds have been found [4], [5], it is still desirable to find new and more structurally diverse scaffolds, and for those reasons we have initiated a fragment-based lead generation campaign [6] using human transthyretin as target protein. In this presentation, we will review our experiences and some of the results observed.

 A. Hörnberg, T. Eneqvist, A. Olofsson, E. Lundgren, A.E SauerEriksson, J. Mol. Biol. 2000, 302, 649-669. [2] E. Lundberg, A. Olofsson, G.T. Westermark, A.E. Sauer-Eriksson. FEBS J 2009, 7, 1999-2011. [3] S.M. Johnson, S. Connelly, I.A. Wilson, J.W. Kelly, J. Med. Chem. 2008, 51, 260-270. [4] T. Klabunde, H.M. Petrassi, V.B. Oza, P. Raman, J.W. Kelly, J.C. Sacchettini. Nat Struct Biol. 2000, 4, 312-21. [5] A. González, J. Quirante, J. Nieto, M.R. Almeida, M.J. Saraiva, A. Planas, G. Arsequell, G. Valencia Bioorg Med Chem Lett. 2009, 17, 5270-3. [6] J.S. Albert, N. Blomberg, A.L. Breeze, A.J. Brown, J.N. Burrows, P.D. Edwards, R.H. Folmer, S. Geschwindner, E.J. Griffen, P.W. Kenny, T. Nowak, L.L. Olsson, H. Sanganee, A.B. Shapiro, Curr. Top. Med. Chem. 2007, 7, 1600-1629.

Keywords: folding, drug design, stability

MS.16.3

Acta Cryst. (2011) A67, C51-C52

Structural biology and medicinal chemistry in neglected diseases of poverty

<u>Glaucius Oliva</u>, Rafaela S. Ferreira, Rafael V.C. Guido, Humberto M. Pereira, Richard C. Garratt, Adriano D. Andricopulo, *Instituto de Física de São Carlos, USP, Caixa Postal 369 - 13560-970 - São Carlos – SP (Brazil)*. E-mail: oliva@ifsc.usp.br

Parasitic diseases are a major global cause of illness, morbidity, long-term disability, and death, with severe medical and psychological